HIV

A workshop of the International Agency for Research on Cancer looked at the gaps in knowledge of four different cancers associated with HIV: Kaposi sarcoma, cervical, lung and anal cancer.

In a JAMA Network Open study published Sept. 11, researchers wanted to take a deeper look into PrEP regimens’ impact on cardiometabolic health, as it is understudied. To do so they examined the risk of incident hypertension and statin use among adult health plan members starting PrEP with tenofovir alafenamide fumarate (TAF) compared adults taking tenofovir disoproxil fumarate (TDF).

The GLAAD HIV Stigma Survey also showed big differences in HIV knowledge among generations.

The tentative approval by the FDA is through the President’s Emergency Plan for AIDS Relief (PEPFAR) program and is supposed to ease regulatory authority submissions, production and distribution in low- and middle-income countries.

Black women living with HIV have improved outcomes when interventions incorporate a support network and when the program emphasized trust.

Researchers of a recent study compared the clinical presentation and treatment outcomes of people with HIV and HIV-negative persons with monkeypox who were treated with tecovirimat, as it was previously unclear if treatment outcomes differed between those with and without HIV.

Some orthopedic surgeons have been reluctant to perform total hip arthroplasty on people with HIV/AIDS. Researchers at UT Southwestern Medical Center found no additional risks from HIV per se.

The company-sponsored study compared Sunlenca (lenacapavir) with Rukobia (fostemsavir) and Trograzo (ibalizumab).

A demonstration project showed that frequent testing reduced the median time to diagnosis by nearly 14 months.

When addressing errors, researchers focused on the individual who made the error and retraining. Lead author Fatima Laher says attention should be shifted to root cause analysis and process improvement.

University of North Carolina researchers found stable and replication-competent HIV in the microglia in the brain even in people with HIV who had been taking antiretroviral therapy for a long time.

Walmart has opened 70 Specialty Pharmacies of the Community locations across the U.S. in June, and is expected to open 80 more in 11 states by the end of the year.

Researchers and clinicians have been wary of treating people living with HIV with Keytruda, Opdivo and other immune checkpoint inhibitors because removing an inhibitory step in the immune response was seen as risky for people with compromised immune systems.

Cannabis may accentuate the effects of HIV on the brain or perhaps may mitigate them because of its anti-inflammatory properties.

The deal, initially tentative, was announced Friday between the administration and those challenging the Affordable Care Act mandate.

Ribó is the faculty advisor to new POCN Center for HIV Excellence that will provide information and resources to providers who may see relatively few patients with HIV.

‘Yes, PrEP is very important and very useful, but its use is complemented extremely by HIV treatment, so you really have to do both,’ says researcher.

CDC researchers estimate an almost 50% decrease in those with uncovered costs associated with HIV preexposure prophylaxis (PrEP). More people who are PrEP eligible have insurance and the cost of PrEP has declined.

A team of researchers studied 22 HIV 'post-treatment controllers' — people whose HIV infections are kept in check even after stopping antiretroviral therapy.

A Kaiser Permanente study shows a close link between HIV RNA levels and low CD4 counts and the risk of heart failure.

Stem cell transplants are not being proposed as treatments for HIV, but this case and a handful of others offer promising confirmation that HIV is not entirely incurable.

The known benefits of antiretroviral therapy (ART) in pregnant persons living with HIV outweigh the risks, which include low-birth weight and metabolic complications for the pregnant person, says the lead author of a review article ART and adverse outcomes published in the New England Journal of Medicine.

Researchers report positive result from a phase 1 trial that show the presence of the antiviral medication in rectal tissue.

Uptake of pre-exposure prophylaxis (PrEP) has been slow. A survey shows that safety and side effects are the top concerns.